Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| STAAR SURGIC | STAA | 10.98% |
| DTS INC | DTSI | 6.89% |
| ANIKA THERAP | ANIK | 6.04% |
| LUMOS NETWOR | LMOS | 5.70% |
| INSTEEL IND | IIIN | 5.28% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Agilent Technologies Inc. (A - Analyst Report), a broad-based OEM of test and measurement equipment has authorized the repurchase of shares up to $500 million of the company’s common stock during fiscal 2013.
Additionally, the company also announced its decision to raise the quarterly dividend by two cents to 12 cents per share. This translates into a 20% increase from the prior dividend. The increased dividend will be paid on April 24, 2013, to stockholders of record on April 24, 2013. Prior to this announcement, Agilent had been paying a quarterly dividend of 10 cents per share.
The strength of Agilent’s business model reflects the company’s commitment toward returning value to shareholders with its strong cash generation capabilities. We believe that the continued share buybacks and dividend hike will increase investor enthusiasm for the shares.
Agilent’s strong balance sheet and cash flows provide financial flexibility in matters of incremental dividend, share repurchases and accretive acquisitions. During the last concluded quarter, Agilent spent $94 million on share repurchases and $34 million on dividends. The cash and cash equivalents were $2.4 billion at quarter-end, having increased $0.5 billion during the quarter. The debt cap ratio was just 28.9%. We remain encouraged by Agilent’s strong cash position and its ability to service its long-term debts.
Agilent reported decent fourth quarter results, with both revenue and earnings per share surpassing our expectations. Agilent’s leadership position, history of innovation, strengthening end markets, stable gross margins, steadily improving operating margins, and position in China are all positives. The increase in dividend indicates that the company is confident about its steady cash flows.
However, an uncertain macro conditions, particularly in the U.S. and Europe and a softer-than-expected earnings guidance increased concerns regarding near-term performance. Hence, Agilent has a Zacks Rank #5 (Strong Sell).
However, all companies with testing portfolios are not doing as bad however. You may consider companies like Teradyne (TER - Analyst Report) and Thermo Fisher Scientific, Inc. (TMO - Analyst Report) which carry a Zacks Rank #2 (Buy) and Danaher Corp. (DHR - Analyst Report) which carries a Zacks Rank #3 (Hold).
Get the full Analyst Report on A - FREE
Get the full Analyst Report on DHR - FREE
Get the full Analyst Report on TMO - FREE
Get the full Analyst Report on TER - FREE